# data[].attributes.body
My top five strengths are achiever, analytical, communication, discipline, and empathy. I have the most talented team to say the least. Alice tends to be the leader within the team, with an extremely strong work ethic. Faith is always pushing us to our limits, and encouraging us to look ahead into the future. Angelica is the one who keeps us all in line, and identifies the factors that may affect certain situations. Andrew is our go getter, and makes things happen to further our success as a team. The final team member Carter is our spokesperson, and plays a vital role in communication when it comes to being the best and fulfilling the success of our product.

# data[].attributes.body
Boston Scientific’s Eluvia peripheral long term drug eluting stent FDA approved. (2018). Medgadget. Retrieved from: https://www.medgadget.com/2018/09/boston-scientifics-eluvia-peripheral-long-term-drug-eluting-stent-fda-approved.html.

Eluvia. (2018). Drug eluting vascular stent. Retrieved from:
http://www.bostonscientific.com/en-US/medical-specialties/vascular-surgery/drug-eluting-therapies/resources.html.

# data[].attributes.headline
FDA approves Eluvia Peripheral Long term DES 

# data[].attributes.subject
FDA approves Eluvia Peripheral Long term DES 

# data[].attributes.attachment_link.readable_text
Boston Scientific won FDA regulatory approval to introduce the Eluvia drug-eluting vascular stent to the U.S. market. The device is the first peripheral stent to offer sustained release of an antiproliferative drug (paclitaxel) for as long as a full year. The drug prevents restenosis, a common condition caused by native tissue growing over the stent.

The Eluvia is based on Boston Scientific's Innova device, which is a self-expanding nitinol stent built to treat superficial femoral and proximal popliteal arteries in the legs.

"In the IMPERIAL trial, the Eluvia stent demonstrated landmark vessel patency and freedom from target lesion revascularization rates, preventing more than 95 percent of patients from needing a reintervention after one year," in a statement said William Gray, M.D., system chief, Division of Cardiovascular Diseases and president, Lankenau Heart Institute at Main Line Health in Wynnewood, Pennsylvania, and co-principal investigator of the IMPERIAL trial that led to the FDA approval. "The Eluvia stent is a breakthrough therapy that marks a significant step forward in the treatment of peripheral artery disease, and now with its approval and commercial availability, it has the potential to make an immediate impact on the quality and value of care that physicians can provide to their patients."

Here's some data from the IMPERIAL trial, according to Boston Sci:

The FDA's approval is based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial. In this trial, patients treated with the Eluvia stent experienced a significantly greater 12-month primary patency of 88.5 percent, compared to 79.5 percent in patients treated with Zilver PTX (p=0.0119). In addition, patients treated with the Eluvia stent experienced half the target lesion revascularization rate of Zilver PTX at 12 months, a 4.5 percent TLR rate for Eluvia versus 9.0 percent TLR rate for the Zilver PTX cohort.

Here are a couple videos Boston Scientific just released about the stent:

Product page: ELUVIA drug-eluting vascular stent system ...

Via: Boston Scientific...

# data[].attributes.attachment_link.title
Boston Scientific's Eluvia Peripheral Long Term Drug Eluting Stent FDA Approved |

# data[].attributes.attachment_link.description
Boston Scientific won FDA regulatory approval to introduce the Eluvia drug-eluting vascular stent to the U.S. market. The device is the first peripheral stent to offer sustained release of an antiproliferative drug (paclitaxel) for as long as a full year. The drug prevents restenosis, a common condition caused by native tissue growing over the stent.

# data[].attributes.headline
Published September 27, 2018 by Medgadget

# data[].attributes.subject
Published September 27, 2018 by Medgadget

# data[].attributes.body
->  via Boston Scientific  <-

# data[].attributes.body
Boston Sicentific has released the first peripheral stent that offers a sustained release of an anti- proliferative drug for one year (Medagadget, 2018).  Studies found that patients treated with the Eluvia stent experienced a significantly greater twelve month period with primary patency of 88.5% versus 79.5% patency with the Zilver PTX (Medgadget, 2018).  Further studies found that Eluvia was found to be preventing more than 95% of patients from needing re-intervention after one year (Medgadget, 2018).  Boston Scientific states that this stent has potential to make an immediate impact on the quality and value of care that physicians can provide to patients now that it has FDA approval (Medgadget, 2018).  It was the Cardiovascular Diseases and president, Lankenau Heart Institute at Main Line Health in Wynnewood, Pennsylvania, and co-principal investigator of the IMPERIAL trial that led to the FDA approval (Medgadget, 2018).

# data[].attributes.body
-> narrowed stent sizing options (Eluvia, 2018)
-> vessel diameter must be greater than 4mm and less than 6mm which limits ability to use on patients (some vessels are larger than 6mm) (Eluvia, 2018).

# data[].attributes.body
In my opinion this is ground breaking therapy for patients with peripheral artery disease. WHY? I have worked for years as a cath lab RN and seen repeat patients, with this stent we could see a decline in the number of revisits a patient has because of this more effective treatment.

# data[].attributes.body
-> Flexibility of stent (Eluvia, 2018)
-> Radial strength (Eluvia, 2018)
-> Stent Fracture resistance (Eluvia, 2018)